The power of a central lab at the touch of a button.
The FDA-cleared, CLIA-Waived, binx io platform uses ultra-rapid polymerase chain reaction (PCR) amplification in conjunction with our proprietary electrochemical detection to achieve sensitivity and specificity on par with central lab performance.
» Contact Us
Clinically-Proven, FDA-Cleared
Clinical performance measured against three FDA-cleared standard-of-care molecular platforms
| TARGET | FEMALE | MALE | ||
|---|---|---|---|---|
| SENSITIVITY | SPECIFICITY | SENSITIVITY | SPECIFICITY | |
| Chlamydia | 96.1% | 99.1% | 92.5% | 99.3% |
| Gonorrhea | 100.0% | 99.9% | 97.3% | 100.0% |
2,445 person (1,523 females; 992 males) multi-center clinical study. As published in JAMA Network Open.
Downloads
Together we can help stop the spread
Sexually transmitted infections (STIs) are on the rise and testing pathways are struggling to keep up..
Traditional pathway
Sample sent to central reference laboratory
Test results available
Treatment may be inappropriate before leaving the clinic or patients may be lost to follow up
binx io pathway
Sample run on binx io point-of-care test
Test results available
Increases treatment compliance with same visit test and treatment